Can AI Stop Humans From Ageing? Sam Altman Is Betting Millions On It

Sam Altman, CEO of OpenAI, has committed nearly $180 million to Retro Biosciences, a startup focused on slowing or reversing human aging through partial cellular reprogramming. Unlike traditional anti-ageing research, Retro Biosciences integrates AI to redesign proteins involved in cellular processes, aiming to combat age-related diseases like Alzheimer’s and heart disease. The company developed a specialized AI model, GPT-4b micro, which OpenAI claims has significantly sped up research timelines and proposed novel protein designs. Retro Biosciences targets the underlying biological mechanisms of aging rather than treating individual diseases separately. This approach, known as partial cellular reprogramming, seeks to reset aging cells without converting them into stem cells. While the science is considered valid by experts, practical treatments remain years away. Altman’s investment reflects a broader trend in Silicon Valley, where tech leaders like Jeff Bezos and Peter Thiel have also funded longevity research. However, Altman’s backing stands out due to its fusion of AI infrastructure, biological science, and computational power. The use of AI in laboratory research marks a significant shift, moving beyond digital applications like email or image generation. OpenAI’s involvement underscores the potential of AI to accelerate scientific breakthroughs in previously untapped fields. Retro Biosciences is not alone in pursuing anti-ageing solutions, but its AI-driven methodology sets it apart. The company’s work could redefine how aging is approached, blending cutting-edge technology with biological innovation.